Skip to main content

This site is a work in progress, with new features and updates based on your feedback.

Search for grants here. To use more advanced features or to apply, go to Grants.gov.

Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed

Agency: Food and Drug Administration

Assistance Listings: 93.103 -- Food and Drug Administration Research

Last Updated: November 30, 2023

Description

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products.


To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. 


The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs. 

Eligibility

Eligible applicants

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education without 501(c)(3)
  • Nonprofits non-higher education with 501(c)(3)

Education

  • Public and state institutions of higher education
  • Private institutions of higher education
  • Independent school districts

Business

  • For-profit organizations other than small businesses
  • Small businesses

Government

  • Federally recognized Native American tribal governments
  • State governments
  • Special district governments
  • County governments
  • City or township governments
  • Public and Indian housing authorities

Miscellaneous

  • Unrestricted
  • Other

Additional information

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Grantor contact information

Description

--

Email

terrin.brown@fda.hhs.gov

terrin.brown@fda.hhs.gov

Documents

No documents are currently available.

Link to additional information

--

Forecasted

Estimated Post Date:

--

Estimated Application Due Date:

--

Estimated Due Date Description:

Not available

Estimated Award Date:

--

Estimated Project Start Date:

--

Fiscal Year:

2024

Application process

This site is a work in progress. Go to www.grants.gov to apply, track application status, and subscribe to updates.

Award

$--

Program Funding

1

Expected awards

$250,000

Award Minimum

$250,000

Award Maximum

Funding opportunity number:

FOR-FD-24-006

Cost sharing or matching requirement:

No

Funding instrument type:

Cooperative agreement

Opportunity Category:

Discretionary

Opportunity Category Explanation:

--

Category of Funding Activity:

Consumer protection

Agriculture

Food and nutrition

Category Explanation:

--

History

Version:

2

Forecast posted date:

November 24, 2023

Archive date:

--

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov